Evoke Wealth’s Revance Therapeutics, Inc. RVNC Stock Holding History

Evoke Wealth’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$8K	–	1187
2022 Q3	$8K	Hold	300	–	–	﹤0.01%	808
2022 Q2	$4K	Buy	+300	New	+$4.62K	﹤0.01%	959
2022 Q1	–	Sell	-115	Closed	-$2K	–	1269
2021 Q4	$2K	Hold	115	–	–	﹤0.01%	1083
2021 Q3	$3K	Hold	115	–	–	﹤0.01%	978
2021 Q2	$3K	Hold	115	–	–	﹤0.01%	1014
2021 Q1	$3K	Hold	115	–	–	﹤0.01%	983
2020 Q4	$3K	Hold	115	–	–	﹤0.01%	851
2020 Q3	$3K	Hold	115	–	–	﹤0.01%	808
2020 Q2	$3K	Buy	+115	New	+$2.27K	﹤0.01%	828
2020 Q1	–	Sell	-426	Closed	-$6.91K	–	1377
2019 Q4	$6.91K	Hold	426	–	–	﹤0.01%	843
2019 Q3	$5.54K	Buy	+426	New	+$5.21K	﹤0.01%	975

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Evoke Wealth's RVNC Position: Q4 2022 in Review

Evoke Wealth sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 300 shares — an estimated $8K sold.

Evoke Wealth first reported a position in RVNC in Q3 2019 and held it in 11 quarters. The position peaked at $8K in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

Evoke Wealth reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Evoke Wealth sold 300 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $8K.
Evoke Wealth first reported a position in Revance Therapeutics, Inc. in Q3 2019 and held it in 11 quarters.
Evoke Wealth's Revance Therapeutics, Inc. position peaked at $8K in Q3 2022.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.